The Neurokinin-1 receptor: a promising antitumor target

  1. Coveñas, Rafael 2
  2. Rodríguez, Francisco D. 1
  3. Muñoz, Miguel
  1. 1 Group GIR-BMD (Bases Moleculares del Desarrollo), University of Salamanca
  2. 2 Laboratory of Neuroanatomy of the Peptidergic Systems, Institute of Neurosciences of Castilla y León (INCYL), University of Salamanca,
  3. 3 Department of Biochemistry and Molecular Biology, Faculty of Chemical Sciences, University of Salamanca
  4. 4 Research Laboratory on Neuropeptides (IBIS), Pediatric Intensive Care Unit, Virgen del Rocío University Hospital, 41012 Seville, Spain
Show affiliations +
Journal:
Receptors

ISSN: 2813-2564

Year of publication: 2022

Volume: 1

Issue: 1

Pages: 72-97

Type: Article

DOI: 10.3390/RECEPTORS1010005 GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Receptors

Sustainable development goals

Abstract

The important role played by the substance P (SP)/neurokinin-1 receptor (NK-1R) system in cancer is reviewed: this includes tumor cell proliferation and migration, anti-apoptotic mechanisms, and angiogenesis. SP, through the NK-1R, behaves as a universal mitogen in cancer cells. The NK-1R is overexpressed in tumor cells and, in addition, affects the viability of cancer cells. NK-1R antagonists counteract all the previous actions mediated by SP through NK-1R. In a concentration-dependent manner, these antagonists promote tumor cell death by apoptosis. Therefore, NK-1R is a potential and promising therapeutic target for cancer treatment by using NK-1R antagonists (e.g., aprepitant) alone or in combination therapy with chemotherapy or radiotherapy.

Bibliographic References

  • Robinson, P., Coveñas, R., and Muñoz, M. Combination therapy of chemotherapy or radiotherapy and the neurokinin-1 receptor antagonist aprepitant: A new antitumor strategy?. Curr. Med. Chem., 2022.
  • Garnier, (2016), Anticancer Res., 36, pp. 5577, 10.21873/anticanres.11143
  • Morgan, (2004), Clin. Oncol., 16, pp. 549, 10.1016/j.clon.2004.06.007
  • Sporn, (1996), Lancet, 347, pp. 1377, 10.1016/S0140-6736(96)91015-6
  • Sánchez, M.L., and Coveñas, R. The galaninergic system: A target for cancer treatment. Cancers, 2022. 14.
  • Sánchez, (2022), Curr. Med. Chem., 29, pp. 3221, 10.2174/0929867328666211027124328
  • Kastin, A.J. Handbook of Biologically Active Peptides, 2013.
  • Colucci, (2008), Br. J. Pharmacol., 155, pp. 198, 10.1038/bjp.2008.268
  • Coveñas, R., and Muñoz, M. Involvement of the substance P/neurokinin-1 receptor system in cancer. Cancers, 2022. 14.
  • Muñoz, M., and Coveñas, R. The neurokinin-1 receptor antagonist aprepitant, a new drug for the treatment of hematological malignancies: Focus on acute myeloid leukemia. J. Clin. Med., 2020. 9.
  • Ebrahimi, (2022), Biochim. Biophys. Acta Mol. Cell. Res., 1869, pp. 119221, 10.1016/j.bbamcr.2022.119221
  • Muñoz, (2020), Expert Opin. Ther. Pat., 30, pp. 527, 10.1080/13543776.2020.1769599
  • Kolorz, (2021), Curr. Oncol., 29, pp. 94, 10.3390/curroncol29010008
  • Zhang, (2022), Cell Death Dis., 13, pp. 41, 10.1038/s41419-021-04485-y
  • Muñoz, (2022), Biomed. Res. Int., 2022, pp. 6291504, 10.1155/2022/6291504
  • González-Moles, M.A., Ramos-García, P., and Esteban, F. Significance of the overexpression of substance P and its receptor NK-1R in head and neck carcinogenesis: A systematic review and meta-analysis. Cancers, 2021. 13.
  • Choi, S. Neurokinin-1 receptor. Encyclopedia of Signaling Molecules, 2018.
  • Huhtaniemi, I., and Martini, L. Encyclopedia of Endocrine Diseases, 2019. Volume 1.
  • Single Nucleotide Polymorphisms. 2022.
  • Farran, (2017), Pharmacol. Res., 117, pp. 303, 10.1016/j.phrs.2017.01.008
  • Xue, (2019), Nat. Commun., 10, pp. 2765, 10.1038/s41467-019-10834-5
  • Meyer, (2006), Proc. Natl. Acad. Sci. USA, 103, pp. 2138, 10.1073/pnas.0507686103
  • Terpager, (2009), J. Recept. Signal Transduct. Res., 29, pp. 235, 10.1080/10799890903154217
  • GPCR Database. 2022.
  • Offermanns, S., and Rosenthal, W. Neurokinin/Tachykin receptors. Encyclopedia of Molecular Pharmacology, 2021.
  • Roush, (1998), FEBS Lett., 428, pp. 291, 10.1016/S0014-5793(98)00553-5
  • Mitsuhashi, (1992), J. Neurosci. Res., 32, pp. 437, 10.1002/jnr.490320315
  • Sagan, (1996), J. Pharmacol. Exp. Ther., 276, pp. 1039
  • Takeda, (1992), J. Neurochem., 59, pp. 740, 10.1111/j.1471-4159.1992.tb09430.x
  • Ramkissoon, (2006), Expert Opin. Biol. Ther., 6, pp. 109, 10.1517/14712598.6.2.109
  • Nakajima, (1992), J. Biol. Chem., 267, pp. 2437, 10.1016/S0021-9258(18)45898-X
  • Holst, (2001), J. Biol. Chem., 276, pp. 19793, 10.1074/jbc.M100621200
  • Khawaja, (1996), Int. J. Biochem. Cell Biol., 28, pp. 721, 10.1016/1357-2725(96)00017-9
  • Muñoz, M., Rosso, M., and Coveñas, R. Neurokinin-1 receptor antagonists against hepatoblastoma. Cancers, 2019. 11.
  • Harris, (1994), Nature, 371, pp. 155, 10.1038/371155a0
  • Protein Data Bank (PDB). 2022.
  • Sehnal, (2021), Nucleic Acids Res., 49, pp. W431, 10.1093/nar/gkab314
  • Li, (2016), Eur. J. Cell Biol., 95, pp. 368, 10.1016/j.ejcb.2016.07.005
  • Zhang, (2016), Peptides, 83, pp. 8, 10.1016/j.peptides.2016.07.004
  • Mou, (2013), J. Biol. Chem., 288, pp. 306, 10.1074/jbc.M112.389783
  • Berger, (2005), J. Neuroimmunol., 164, pp. 48, 10.1016/j.jneuroim.2005.03.016
  • Muñoz, (2014), Amino Acids, 46, pp. 1727, 10.1007/s00726-014-1736-9
  • Muñoz, (2012), Expert Opin. Ther. Pat., 22, pp. 735, 10.1517/13543776.2012.697153
  • Rost, (2006), Med. Monatsschr. Pharm., 29, pp. 200
  • Kramer, (1998), Science, 281, pp. 1640, 10.1126/science.281.5383.1640
  • Keller, (2006), Biol. Psychiatry, 59, pp. 216, 10.1016/j.biopsych.2005.07.013
  • Deng, (2019), J. Cell. Mol. Med., 23, pp. 7961, 10.1111/jcmm.14230
  • Friess, (2003), Lab. Investig., 83, pp. 731, 10.1097/01.LAB.0000067499.57309.F6
  • Nizam, (2018), Biomed. Pharmacother., 108, pp. 263, 10.1016/j.biopha.2018.09.013
  • Ge, (1989), Zhonghua Jie He He Hu Xi Za Zhi, 12, pp. 347
  • Mohammadi, (2020), Mol. Biol. Rep., 47, pp. 4263, 10.1007/s11033-020-05532-1
  • Ebrahimi, (2020), Clin. Genet., 98, pp. 322, 10.1111/cge.13750
  • Zhang, (2019), Cell Prolif., 52, pp. e12527, 10.1111/cpr.12527
  • Fong, (1992), Mol. Pharmacol., 41, pp. 24
  • Zhou, (2013), Breast Cancer Res. Treat., 140, pp. 49, 10.1007/s10549-013-2599-6
  • Lai, (2008), Proc. Natl. Acad. Sci. USA, 105, pp. 12605, 10.1073/pnas.0806632105
  • Simeonidis, (2003), Proc. Natl. Acad. Sci. USA, 100, pp. 2957, 10.1073/pnas.0530112100
  • Goode, (2003), J. Cell. Physiol., 197, pp. 30, 10.1002/jcp.10234
  • Rosso, (2012), Sci. World J., 2012, pp. 381434
  • Spitsin, (2018), J. Leukoc. Biol., 103, pp. 1043, 10.1002/JLB.3MIR0817-348R
  • Berger, (2014), J. Hepatol., 60, pp. 985, 10.1016/j.jhep.2013.12.024
  • Singh, (2000), Proc. Natl. Acad. Sci. USA, 97, pp. 1388, 10.1073/pnas.97.1.388
  • Mozafari, (2021), Mol. Biol. Rep., 49, pp. 1067, 10.1007/s11033-021-06928-3
  • Douglas, (2011), Ann. N. Y. Acad. Sci., 1217, pp. 83, 10.1111/j.1749-6632.2010.05826.x
  • Henssen, (2017), Oncotarget, 8, pp. 430, 10.18632/oncotarget.13440
  • Pohl, (2017), Anticancer Res., 37, pp. 6079
  • Harford-Wright, (2014), Neuroscience, 261, pp. 85, 10.1016/j.neuroscience.2013.12.027
  • Golestaneh, (2022), Mol. Biol. Rep., 49, pp. 4893, 10.1007/s11033-022-07348-7
  • Zhou, (2020), Life Sci., 256, pp. 117674, 10.1016/j.lfs.2020.117674
  • Beirith, I., Renz, B.W., Mudusetti, S., Ring, N.S., Kolorz, J., Koch, D., Bazhin, A.V., Berger, M., Wang, J., Angele, M.K., Identification of the neurokinin-1 receptor as targetable stratification factor for drug repurposing in pancreatic cancer. Cancers, 2021. 13.
  • Rodríguez, (2022), Receptors, 1, pp. 54, 10.3390/receptors1010004
  • Wang, (2019), Biochem. Biophys. Res. Commun., 514, pp. 1210, 10.1016/j.bbrc.2019.05.092
  • Davoodian, (2019), Mol. Biol. Rep., 46, pp. 1285, 10.1007/s11033-019-04599-9
  • Hennig, (1995), Int. J. Cancer, 61, pp. 786, 10.1002/ijc.2910610608
  • Gharaee, (2018), Mol. Biol. Rep., 45, pp. 2257, 10.1007/s11033-018-4387-1
  • Ziche, (1990), Microvasc. Res., 40, pp. 264, 10.1016/0026-2862(90)90024-L
  • Muñoz, M., and Coveñas, R. The neurokinin-1 receptor antagonist aprepitant: An intelligent bullet against cancer?. Cancers, 2020. 12.
  • Muñoz, (2013), Peptides, 48, pp. 1, 10.1016/j.peptides.2013.07.024
  • Koon, (2007), Proc. Natl. Acad. Sci. USA, 104, pp. 2013, 10.1073/pnas.0610664104
  • Fulenwider, (2018), J. Neuroinflammation, 15, pp. 60, 10.1186/s12974-018-1098-4
  • Walczak-Drzewiecka, (2008), J. Immunol., 181, pp. 1665, 10.4049/jimmunol.181.3.1665
  • Muñoz, (2010), Investig. New Drugs, 28, pp. 187, 10.1007/s10637-009-9218-8
  • Muñoz, (2010), Lab. Investig., 90, pp. 1259, 10.1038/labinvest.2010.92
  • Muñoz, (2013), Expert Opin. Drug Saf., 12, pp. 673, 10.1517/14740338.2013.804059
  • Mehboob, (2022), Folia Neuropathol., 60, pp. 165, 10.5114/fn.2022.116469
  • Muñoz, (2010), Curr. Med. Chem., 17, pp. 504, 10.2174/092986710790416308
  • Li, (2000), J. Hematother. Stem Cell Res., 9, pp. 445, 10.1089/152581600419107
  • Dubon, (2015), Exp. Ther. Med., 9, pp. 1185, 10.3892/etm.2015.2291
  • Kim, (2015), Spine J., 15, pp. 2055, 10.1016/j.spinee.2015.04.032
  • Garnier, (2015), Int. J. Oncol., 47, pp. 151, 10.3892/ijo.2015.3016
  • Muñoz, (2019), Lett. Drug Des. Discov., 16, pp. 1110, 10.2174/1570180816666190221091955
  • Zhou, (2019), Cancer Res. Treat., 18, pp. 1
  • Castro, (2005), Clin. Exp. Metastasis, 22, pp. 621, 10.1007/s10585-006-9001-6
  • Chen, (2016), OncoTargets Ther., 9, pp. 3595
  • Garnier, (2016), Oncol. Lett., 11, pp. 870, 10.3892/ol.2015.3951
  • Dong, (2015), Gene, 560, pp. 205, 10.1016/j.gene.2015.02.002
  • Feng, (2011), Cell Biol. Int., 35, pp. 623, 10.1042/CBI20100229
  • González-Moles, (2009), Oncol. Rep., 22, pp. 1325, 10.3892/or_00000571
  • Al-Keilani, M.S., Elstaty, R.I., Alqudah, M.A., and Alkhateeb, A.M. Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index. PLoS ONE, 2021. 16.
  • Al-Keilani, (2022), Int. J. Breast Cancer, 2022, pp. 4987912, 10.1155/2022/4987912
  • Muñoz, (2020), Anticancer Agents Med. Chem., 19, pp. 92, 10.2174/1871520618666180420165401
  • Muñoz, (2015), J. Biosci., 40, pp. 441, 10.1007/s12038-015-9530-8
  • Gutierrez, (2018), Cancer Cell Int., 18, pp. 216, 10.1186/s12935-018-0707-8
  • García-Recio, (2013), Cancer Res., 73, pp. 6424, 10.1158/0008-5472.CAN-12-4573
  • Mayordomo, (2012), J. Cell. Physiol., 227, pp. 1358, 10.1002/jcp.22848
  • Castagliuolo, (2000), J. Biol. Chem., 275, pp. 26545, 10.1074/jbc.M003990200
  • Kast, (2010), J. Clin. Pharm. Ther., 35, pp. 657, 10.1111/j.1365-2710.2009.01148.x
  • Zhang, (2017), J. Biol. Chem., 292, pp. 8933, 10.1074/jbc.M116.770420
  • Almendro, (2010), Curr. Drug Targets, 11, pp. 1169, 10.2174/138945010792006807
  • Yamaguchi, (2005), Cancer Chem. Pharmacol., 56, pp. 585, 10.1007/s00280-005-1030-3
  • Esteban, F., Ramos-García, P., Muñoz, M., and González-Moles, M.A. Substance P and neurokinin 1 receptor in chronic inflammation and cancer of the head and neck: A review of the literature. Int. J. Environ. Res. Public Health, 2021. 19.
  • De Fea, (2000), Proc. Natl. Acad. Sci. USA, 97, pp. 11086, 10.1073/pnas.190276697
  • Bockmann, (2001), Peptides, 22, pp. 661, 10.1016/S0196-9781(01)00376-X
  • Hartmann, (2009), Clin. Cancer Res., 15, pp. 4538, 10.1158/1078-0432.CCR-08-2878
  • Breuleux, (2009), Mol. Cancer Ther., 8, pp. 742, 10.1158/1535-7163.MCT-08-0668
  • Chen, (2011), J. Pharmacol. Exp. Ther., 337, pp. 155, 10.1124/jpet.110.175786
  • Akazawa, (2009), J. Neurochem., 109, pp. 1079, 10.1111/j.1471-4159.2009.06032.x
  • Medrano, (1994), Neurosci. Lett., 167, pp. 14, 10.1016/0304-3940(94)91017-0
  • Ougolkov, (2005), Cancer Res., 65, pp. 2076, 10.1158/0008-5472.CAN-04-3642
  • Zeng, J., Liu, D., Qiu, Z., Huang, Y., Chen, B., Wang, L., Xu, H., Huang, N., Liu, L., and Li, W. GSK3β overexpression indicates poor prognosis, and its inhibition reduces cell proliferation and survival of non-small cell lung cancer cells. PLoS ONE, 2014. 9.
  • Wierstra, (2011), Biochem. Biophys. Res. Commun., 413, pp. 230, 10.1016/j.bbrc.2011.08.075
  • Ogo, (1996), J. Neurochem., 67, pp. 1813, 10.1046/j.1471-4159.1996.67051813.x
  • Singh, (2021), Indian J. Surg. Oncol., 12, pp. 93, 10.1007/s13193-020-01210-7
  • Ho, (1996), J. Neuroimmunol., 71, pp. 73, 10.1016/S0165-5728(96)00132-4
  • Weller, (1991), J. Neurol. Sci., 104, pp. 215, 10.1016/0022-510X(91)90313-V
  • Frei, (1992), Despite the presence of inducing signals, GM-CSF is not expressed in vivo. J. Immunol., 148, pp. 3140
  • Lotz, (1988), Science, 241, pp. 1218, 10.1126/science.2457950
  • Muñoz, (2015), Cancers, 7, pp. 1215, 10.3390/cancers7030832
  • Gillespie, (2011), Proc. Natl. Acad. Sci. USA, 108, pp. 17420, 10.1073/pnas.1114275108
  • Molinos-Quintana, (2019), Investig. New Drugs, 37, pp. 17, 10.1007/s10637-018-0607-8
  • Patel, (2021), J. Pain Symptom Manag., 62, pp. e225, 10.1016/j.jpainsymman.2021.02.007
  • Muñoz, (2019), Acta Derm. Venereol., 99, pp. 620, 10.2340/00015555-3148
  • Bashash, (2018), Int. J. Biochem. Cell Biol., 103, pp. 105, 10.1016/j.biocel.2018.08.010
  • Florea, (2011), Cancers, 3, pp. 1351, 10.3390/cancers3011351
  • Rodriguez, E., Pei, G., Zhao, Z., Kim, S.T., German, A., and Robinson, P. Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple-negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis. Cancers, 2021. 13.
  • Lee, (2010), Circulation, 121, pp. 675, 10.1161/CIRCULATIONAHA.109.902221
  • Ilmer, (2015), Mol. Cancer Ther., 14, pp. 2712, 10.1158/1535-7163.MCT-15-0206
  • Ma, (2016), Int. J. Gynecol. Cancer, 26, pp. 845, 10.1097/IGC.0000000000000683
  • Lang, (2004), Int. J. Cancer, 112, pp. 231, 10.1002/ijc.20410
  • Li, (2013), Mol. Cancer Res., 11, pp. 294, 10.1158/1541-7786.MCR-12-0609
  • Rodríguez, (2014), Int. J. Cancer, 134, pp. 1034, 10.1002/ijc.28433
  • Muñoz, (2020), Mini Rev. Med. Chem., 20, pp. 408, 10.2174/1389557519666191112152642
  • Li, (2021), Biomaterials, 276, pp. 121003, 10.1016/j.biomaterials.2021.121003
  • Razmgah, (2022), Mol. Biol. Rep., 49, pp. 9307, 10.1007/s11033-022-07771-w
  • Bielenberg, (2015), Cancer J., 21, pp. 267, 10.1097/PPO.0000000000000138
  • Orimo, (2006), Cell Cycle, 5, pp. 1597, 10.4161/cc.5.15.3112
  • Watnick, (2012), Cold Spring Harb. Perspect. Med., 2, pp. a006676, 10.1101/cshperspect.a006676
  • Deryugina, (2015), Matrix Biol., 44–46, pp. 94, 10.1016/j.matbio.2015.04.004
  • Amin, (2008), Microvasc. Res., 76, pp. 15, 10.1016/j.mvr.2008.01.002
  • Luo, (1996), Cancer Res., 1, pp. 4983
  • Ji, (2022), J. Immunol. Res., 2022, pp. 5582811, 10.1155/2022/5582811
  • Nagakawa, (1998), Cancer Lett., 133, pp. 27, 10.1016/S0304-3835(98)00186-4
  • Tebas, (2015), AIDS, 29, pp. 931, 10.1097/QAD.0000000000000638
  • Mehner, (2014), Oncotarget, 5, pp. 2736, 10.18632/oncotarget.1932
  • Javid, (2020), Mol. Biol. Rep., 47, pp. 2253, 10.1007/s11033-020-05330-9
  • Saito, (2013), Ann. Oncol., 24, pp. 1067, 10.1093/annonc/mds541
  • García-Recio, (2015), BioMed. Res. Int., 2015, pp. 495704, 10.1155/2015/495704
  • Girish, (2007), Indian J. Cancer, 44, pp. 25, 10.4103/0019-509X.31164
  • Muñoz, (2019), Mol. Clin. Oncol., 11, pp. 50
  • Tattersall, (2000), Neuropharmacology, 39, pp. 652, 10.1016/S0028-3908(99)00172-0
  • Majkowska-Pilip, A., Halik, P.K., and Gniazdowska, E. The significance of NK1 receptor ligands and their application in targeted radionuclide tumor therapy. Pharmaceutics, 2019. 11.
  • Halik, P.K., Lipiński, P.F.J., Matalińska, J., Koźmiński, P., Misicka, A., and Gniazdowska, E. Radiochemical synthesis, and evaluation of novel radio conjugates of neurokinin 1 receptor antagonist aprepitant dedicated for NK-1R-positive tumors. Molecules, 2020. 25.
  • Sooho, Y., Jieun, A., Changhee, P., Dohyun, K., and Jaehwi, L. Design, and characterization of phosphatidylcholine-based solid dispersions of aprepitant for enhanced solubility and dissolution. Pharmaceutics, 2020. 12.
  • Olver, (2007), Int. J. Nanomed., 2, pp. 13, 10.2147/nano.2007.2.1.13
  • Muñoz, (2014), Int. J. Oncol., 44, pp. 137, 10.3892/ijo.2013.2164
  • Legi, A., Rodriguez, E., Eckols, T.K., Mistry, C., and Robinson, P. Substance P antagonism prevents chemotherapy-induced cardiotoxicity. Cancers, 2021. 13.
  • García-Aranda, M., Téllez, T., McKenna, L., and Redondo, M. Neurokinin-1 receptor (NK-1R) antagonists as a new strategy to overcome cancer resistance. Cancers, 2022. 14.
  • Castro-Obregón, (2004), J. Biol. Chem., 279, pp. 17543, 10.1074/jbc.M312363200
  • Lim, (2017), Sci. Rep., 7, pp. 9417, 10.1038/s41598-017-09639-7
  • Shi, (2021), Adv. Sci., 8, pp. e2101936, 10.1002/advs.202101936
  • Ge, (2019), Proc. Natl. Acad. Sci. USA, 116, pp. 19635, 10.1073/pnas.1908998116
  • Javid, (2019), J. Physiol. Biochem., 75, pp. 415, 10.1007/s13105-019-00697-1
  • Bayati, (2018), Anticancer Drugs, 29, pp. 243, 10.1097/CAD.0000000000000591
  • Yun, (2005), J. Cell Sci., 118, pp. 313, 10.1242/jcs.01601
  • Javid, (2021), Biomed. Res. Int., 2021, pp. 8808214, 10.1155/2021/8808214
  • Fu, (2015), Stem Cells Int., 2015, pp. 270328, 10.1155/2015/270328
  • Yu, (2012), Front. Biosci., 4, pp. 1528, 10.2741/e478
  • Korfi, (2021), Biochem. Res. Int., 2021, pp. 6620708, 10.1155/2021/6620708
  • Ghahremani, (2021), Iran J. Basic Med. Sci., 24, pp. 499
  • Rezaei, (2022), BioMed. Res. Int., 2022, pp. 8540403, 10.1155/2022/8540403
  • Muñoz, (2012), Investig. New Drugs, 30, pp. 529, 10.1007/s10637-010-9594-0
  • Ito, (2014), Lung Cancer, 84, pp. 259, 10.1016/j.lungcan.2014.03.017
  • Robinson, (2016), BioMed. Res. Int., 2016, pp. 1959270, 10.1155/2016/1959270
  • Un, (2020), Eur. J. Pharmacol., 880, pp. 173168, 10.1016/j.ejphar.2020.173168
  • Kitchens, (2009), FASEB J., 23, pp. 756.13, 10.1096/fasebj.23.1_supplement.756.13
  • Alfieri, (2004), Arch. Venez. Farmacol. Ter., 23, pp. 61
  • Alfieri, (2000), Naunyn Schmiedebergs Arch. Pharmacol., 361, pp. 334, 10.1007/s002109900196
  • Muñoz, (2014), Int. J. Oncol., 45, pp. 1658, 10.3892/ijo.2014.2565
  • Kast, (2016), J. Neurooncol., 126, pp. 425, 10.1007/s11060-015-1996-6
  • WO2015101596. Neurokinin-1 Receptor Antagonists for Use in a Method of Prevention of Cancer, 2015.
  • US2020054620. Use of Non-Peptidic NK1 Receptor Antagonists for the Production of Apoptosis in Tumor Cells, 2020.
  • Bukowski, K., Kciuk, M., and Kontek, R. Mechanisms of multi-drug resistance in cancer chemotherapy. Int. J. Mol. Sci., 2020. 21.
  • Lindsey, (2014), Am. J. Physiol. Heart Circ. Physiol., 307, pp. H1379, 10.1152/ajpheart.00099.2014
  • Bhagat, (2020), Adv. Exp. Med. Biol., 1257, pp. 181, 10.1007/978-3-030-43032-0_15
  • Park, (2012), Carcinogenesis, 33, pp. 1843, 10.1093/carcin/bgs167
  • US2019092802. Antagonists of NK1 Receptors Derived from Carbohydrates, Production Methods, and Medical Use, 2019.
  • Berhardt, (2022), Advances in Medicine and Biology, Volume 194, pp. 151
  • Snider, (1991), Science, 251, pp. 435, 10.1126/science.1703323
  • Hale, (1998), J. Med. Chem., 41, pp. 4607, 10.1021/jm980299k
  • Chen, (2019), Nat. Commun., 10, pp. 638, 10.1038/s41467-019-08568-5
  • KingDraw Free Software. 2022.
  • Recio, (2017), Eur. J. Med. Chem., 138, pp. 644, 10.1016/j.ejmech.2017.06.056
  • Muñoz, (2022), Arch. Bronconeumol., 58, pp. 727, 10.1016/j.arbres.2022.05.004